## Kasia Stepniewska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3215785/publications.pdf

Version: 2024-02-01

40 papers 1,944 citations

304743 22 h-index 35 g-index

41 all docs

41 docs citations

41 times ranked

2386 citing authors

#	Article	IF	CITATIONS
1	Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal, 2022, 21, 106.	2.3	1
2	Antimicrobial resistance patterns in bacteria causing febrile illness in Africa, South Asia, and Southeast Asia: a systematic review of published etiological studies from 1980-2015. International Journal of Infectious Diseases, 2022, 122, 612-621.	3 <b>.</b> 3	6
3	A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?. PLoS Neglected Tropical Diseases, 2021, 15, e0009144.	3.0	34
4	Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2021, 15, e0009302.	3.0	12
5	Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. Lancet Infectious Diseases, The, 2020, 20, 943-952.	9.1	25
6	The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Medicine, 2020, 18, 47.	5 <b>.</b> 5	22
7	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Medicine, 2020, 17, e1003393.	8.4	32
8	Title is missing!. , 2020, 17, e1003393.		0
9	Title is missing!. , 2020, 17, e1003393.		O
10	Title is missing!. , 2020, 17, e1003393.		0
11	Title is missing!. , 2020, 17, e1003393.		O
12	Title is missing!. , 2020, 17, e1003393.		0
13	The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2019, 17, 151.	5 <b>.</b> 5	34
14	The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	8.4	27
15	Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study. BMC Medical Research Methodology, 2019, 19, 107.	3.1	5
16	Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting. BMC Medical Research Methodology, 2019, 19, 215.	3.1	3
17	Magnitude and pattern of improvement in processes of care for hospitalised children with diarrhoea and dehydration in Kenyan hospitals participating in a clinical network. Tropical Medicine and International Health, 2019, 24, 73-80.	2.3	9
18	Handling missing data in propensity score estimation in comparative effectiveness evaluations: a systematic review. Journal of Comparative Effectiveness Research, 2018, 7, 271-279.	1.4	29

#	Article	IF	Citations
19	Risk factors for mortality and effect of correct fluid prescription in children with diarrhoea and dehydration without severe acute malnutrition admitted to Kenyan hospitals: an observational, association study. The Lancet Child and Adolescent Health, 2018, 2, 516-524.	5.6	26
20	Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
21	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Medicine, 2018, 15, e1002579.	8.4	47
22	Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges. Malaria Journal, 2017, 16, 430.	2.3	14
23	Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Medicine, 2016, 13, e1001997.	8.4	142
24	Numerical Distributions of Parasite Densities During Asymptomatic Malaria. Journal of Infectious Diseases, 2016, 213, 1322-1329.	4.0	108
25	Bayesian hierarchical regression on clearance rates in the presence of "lag―and "tail―phases with an application to malaria parasites. Biometrics, 2015, 71, 751-759.	1.4	4
26	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Medicine, 2015, 13, 66.	5.5	37
27	Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal of Tropical Medicine and Hygiene. 2014. 91. 833-843.	1.4	204
28	In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malaria Journal, 2012, 11, 355.	2.3	115
29	In Vivo Parasitological Measures of Artemisinin Susceptibility. Journal of Infectious Diseases, 2010, 201, 570-579.	4.0	133
30	A Phase III, Randomized, Non-Inferiority Trial to Assess the Efficacy and Safety of Dihydroartemisinin-Piperaquine in Comparison with Artesunate-Mefloquine in Patients with Uncomplicated Plasmodium falciparum Malaria in Southern Laos. American Journal of Tropical Medicine and Hygiene, 2010, 83, 1221-1229.	1.4	31
31	Population pharmacokinetics of artesunate and amodiaquine in African children. Malaria Journal, 2009, 8, 200.	2.3	62
32	Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. PLoS ONE, 2009, 4, e4551.	2.5	212
33	Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malaria Journal, 2008, 7, 249.	2.3	74
34	The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria. Malaria Journal, 2008, 7, 149.	2.3	42
35	Overestimating resistance in field testing of malaria parasites: simple methods for estimating high EC50 values using a Bayesian approach. Malaria Journal, 2007, 6, 4.	2.3	7
36	Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrugâ€resistant falciparum malaria. Tropical Medicine and International Health, 2007, 12, 201-208.	2.3	88

3

#	Article	lF	CITATION
37	Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malaria Journal, 2006, 5, 127.	2.3	60
38	Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet, The, 2006, 367, 2075-2085.	13.7	133
39	An open label randomized comparison of mefloquine?artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Tropical Medicine and International Health, 2006, 11, 1653-1660.	2.3	50
40	In Vivo Assessment of Drug Efficacy against Plasmodium falciparum Malaria: Duration of Follow-Up. Antimicrobial Agents and Chemotherapy, 2004, 48, 4271-4280.	3.2	95